October 26, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Dear Sir,

Subject: **Update on the Company's Baddi (India) Facility**

We refer to our letter dated 22nd September 2022 informing you about the continuation of "Official Action Indicated" OAI status of the Company's Baddi (India) manufacturing facility by US FDA following the US FDA inspection conducted in June 2022. We now wish to inform you that the US FDA has placed the Baddi (India) facility under import alert 66-40.

The US revenues from products supplied from this facility contributed to 1-2% of FY22 total revenues for the Company.

The Company will engage with the agency to resolve the import alert at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2022.10.26 20:19:01 +05'30'

Harish Kuber
Company Secretary & Compliance Officer